+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effects of octreotide on portal hemodynamics in patients with liver cirrhosis



The effects of octreotide on portal hemodynamics in patients with liver cirrhosis



Zhonghua Nei Ke Za Zhi 43(1): 16-18



To compare the portal hemodynamic effects of different doses of somatostatin analogue octreotide (sandostatin) with beta-blocker (propranolol) on prevention of early variceal re-bleeding in patients with cirrhotic portal hypertension. Thirty patients of cirrhosis with moderate to severe esophageal varices were randomly allocated into three groups. 10 patients in group A were given propranolol 10-20 mg orally three times a day for 7 days; 10 patients in group B were administrated octreotide 0.05 mg subcutaneously two times a day for 3 days, while 10 patients in group C received octreotide 0.1 mg subcutaneously two times a day for 3 days. The postprandial vessel diameter, maximal and average flow velocity (Vmax/V) and flow volume of portal vein (PV), splenic vein (SV) and superior mesenteric vein (SMV) were measured before and after therapy by using Echo-Doppler technology. There was a trend of decrease of the vessel diameter in all the three groups, but with no significant difference. However, the average velocity and flow volume of PV were significantly diminished in the propranolol group (P < 0.05), while there was no statistical change of them in SV and SMV groups. In octreotide 0.05 mg and 0.1 mg group, the average velocity and flow volume of PV, SV and SMV were significantly decreased (P > 0.05). Besides, octreotide 0.1 mg group but not 0.05 mg group was more active in decreasing flow volume of PV as compared with the propranolol group, while both octreotide groups were superior to the propranolol group in decreasing flow volume of SV and SMV. Octreotide may have potential prophylactic effect in prevention of early variceal re-bleeding in cirrhotic patients with portal hypertension.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050623580

Download citation: RISBibTeXText

PMID: 14990014


Related references

Effects of two different dosages of octreotide on portal pressure and hepatic hemodynamics in cirrhotic portal hypertensive patients after portal-azygous devascularization and splenectomy. Zhonghua Nei Ke Za Zhi 46(4): 290-293, 2007

Effects of molsidomine on hepatic hemodynamics in patients with liver cirrhosis and portal hypertension. Gastroenterology 100(5 Part 2): A754, 1991

Effects of bathing in hot water on portal hemodynamics in healthy subjects and in patients with compensated liver cirrhosis. Internal Medicine 34(7): 628-631, 1995

Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. Hepatology 8(4): 850-854, 1988

Acute and long-term effects of molsidomine on portal and cardiac hemodynamics in patients with cirrhosis of the liver. Intensiv- und Notfallbehandlung 17(4): 184-190, 1992

Effects of canrenoate potassium, an aldosterone antagonist on portal hemodynamics in patients with compensated liver cirrhosis. Hepato-Gastroenterology 43(10): 887-892, 1996

Effects of molsidomine on portal pressure systemic hemodynamics and liver elimination function in patients with alcoholic cirrhosis. Gastroenterology 96(5 Part 2): A671, 1989

48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study. Digestive Diseases and Sciences 45(5): 1019-1027, 2000

Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 96(4): 1110-1118, 1989

Effects of changes in central hemodynamics and hormonal systems of its regulation on the etiology of portal hypertension complications in patients with liver cirrhosis. Klinicheskaia Meditsina 73(4): 99, 1995

Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut and Liver 1(2): 159-164, 2007

Duplex Doppler sonography for observation of portal venous hemodynamics in patients with liver cirrhosis and portal hypertension before and after surgery of portopulmonary shunting. Chinese Journal of Ultrasound in Medicine 9(3): 171-173, 1993

Reduction of portal pressure by chronic administration of isosorbide dinitrate in patients with cirrhosis: effects on systemic and splanchnic hemodynamics and liver function. American Journal of Gastroenterology 87(9): 1160-1164, 1992

Octreotide does not improve renal function in patients with liver cirrhosis and severe portal hypertension. Journal of Hepatology 13(Suppl. 2): S139, 1991

Hemodynamic effects of octreotide in patients with cirrhosis and portal hypertension. Journal of Hepatology 23(Suppl. 1): 114, 1995